A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

PHASE1TerminatedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

September 22, 2017

Primary Completion Date

April 17, 2019

Study Completion Date

April 17, 2019

Conditions
Heart Failure
Interventions
DRUG

Placebo

Specified dose on specified days

DRUG

BMS-986224

Specified dose on specified days

Trial Locations (18)

12808

Vseobecna Fakultni Nemocnice v Praze, Prague

15706

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela

28034

Hospital Universitario Ramon Y Cajal, Madrid

28040

Hospital Universitario Fundacion Jimenez Diaz, Madrid

36312

Hospital Alvaro Cunqueiro, Vigo

46010

Hospital Clinico Universitario de Valencia, Valencia

401 13

Krajska zdravotni - Masarykova nemocnice v Usti nad Labem, Ústí nad Labem

7416 SE

Deventer Ziekenhuis, Deventer

9713 GZ

Universitair Medisch Centrum Groningen, Groningen

9728 NZ

PRA Health Sciences - Groningen, Groningen

2035 RC

Spaarne Gasthuis - Haarlem-Zuid, Haarlem

8601 ZR

D & A Research and Genetics, Sneek

20-954

Samodzielny Publiczny Szpital Kliniczny Number 4 w Lublinie, Lublin

50-981

4th Wojskowy Szpital Kliniczny z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Wroclaw

B15 2TH

University Hospitals Birmingham NHS Foundation Trust, Birmingham

DD1 9SY

NHS Tayside, Dundee

EH16 4SB

The University of Edinburgh, Edinburgh

Unknown

Richmond Pharmacology, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY